Stryker Corporation · NYSE:SYK

Stryker — 35th Annual Canaccord Genuity Growth Conference (August 2015)

11 slides from Stryker's conference presentation, Aug 12, 2015

  1. Slide 1: Stryker

    STRYKER Katherine Owen Vice President, Strategy & Investor Relations August 12, 2015

  2. Slide 2: Forward Looking Statement

    FORWARD LOOKING STATEMENT Certain statements made in the presentation may contain information that includes or is based on forward-looking statements within the meaning of the federal securities law that are subject to various risks and uncertainties that could cause our actual results to differ mat

  3. Slide 3: Global MedTech Leader

    GLOBAL MEDTECH LEADER Neuro Powered Instruments • Pursuing global market 3% CMF Knees 2% 14% leadership in three Neurovascular 5% segments Spine 8% Hips 13% Sustainability Solutions 2% 2014 Sales • Growing through Medical 8% $9.7B business unit Trauma & Extremities 13% specialization Endoscopy 14% O

  4. Slide 4: Growth at the High End of MedTech

    GROWTH AT THE HIGH END OF MEDTECH 7.0% Organic Revenue Growth* 5.5 - 6.5% 6.0% 5.8% 5.1% 5.0% 4.2% 4.0% 3.0% 2.6% 2.8% 2.4% 2.0% 1.0% 0.0% 2012 2013 2014 2015E MedTech Market** Stryker * Removes the impact of changes in foreign currency exchange rates, divestitures (not applicable to Stryker) and th

  5. Slide 5: Key Growth Drivers

    KEY GROWTH DRIVERS • Accelerate growth in Europe with Trans-Atlantic operating model • Expand Trauson outside of China • Continued expansion of emerging markets International (Developed) 2014 Sales United States • Recover in Japan 24% 68% $9.7B Emerging Markets 8% 5

  6. Slide 6: Focused on Innovation

    FOCUSED ON INNOVATION • Demonstrating commitment to internal innovation +12% 4 Year CAGR R&D* Nearly 2x the MedTech • Driving innovation with average R&D CAGR** products and services • Focused on improved outcomes & delivering greater cost savings/efficiencies * 4 year CAGR is for periods 2011 – 201

  7. Slide 7: Operating Leverage Initiatives

    OPERATING LEVERAGE INITIATIVES • Amplify the GQ&O cost reduction program • Reduce inventories through product rationalization • Drive SG&A savings via shared services • Simplify and rationalize our information technology footprint 7

  8. Slide 8: Continued Strength Through M&A

    CONTINUED STRENGTH THROUGH M&A Ascent Patient Safety Technologies Muka Metal Porex Concentric OtisMed Trauson Pivot Medical CHG Hospital Beds Orthovita 2009 2010 2011 2012 2013 2014 2015 Memometal MAKO Gaymar Small Bone Surpass Innovations Sonopet Berchtold Holding Neurovascular • Targeting core and

  9. Slide 9: Capital Deployment

    CAPITAL DEPLOYMENT • M&A to drive sales growth and innovation Focused on driving sales growth in core and adjacent markets Guidelines: - generally to exceed cost of capital by year 3 - target 12.5% + IRR • Dividend growth Dividend per share CAGR of 20% since 2010 Committed to increasing the dividend

  10. Slide 10: Stryker Advantage

    STRYKER ADVANTAGE POSITIONED WELL FOR THE FUTURE • Global MedTech leader • Focused on innovation • Accelerating global growth • Opportunities to drive operational leverage • Healthy cash flow and balance sheet 10

  11. Slide 11: Stryker

    SG fo. \ ©) Nea STRYKER

Stryker — 35th Annual Canaccord Genuity Growth Conference (August 2015) on 6ix